Form 4: Halozyme Therapeutics CFO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Nicole LaBrosse, CFO of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 22, 2024, Nicole LaBrosse, the SVP and CFO of Halozyme Therapeutics, exercised options to purchase 5,000 shares of common stock at a price of $22.50.
- She then sold 4,008 shares at a weighted average price of $53.853, with individual sales ranging from $53.17 to $54.15.
- Additionally, she sold 992 shares at a weighted average price of $54.253, with individual sales ranging from $54.17 to $54.325.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 22, 2024.
- Following these transactions, LaBrosse directly owns 15,480 shares of Halozyme Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to manage their stock holdings and avoid accusations of trading on inside information.
Key Dates
| Date | Description |
|---|---|
| July 1, 2015 | Date the option was granted. |
| March 22, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| July 22, 2024 | Date of the option exercise and stock sales. |
| July 23, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.